Levothyroxine formulation with acacia
US9271951B2 · kind B2 · utility
5Cited by
9References
20Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 21, 2012 |
| Grant date | Mar 1, 2016 |
| Priority date | — |
| Expiry date | Dec 21, 2032 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K36/48
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A pharmaceutical composition comprising thyroxine, acacia, and an antioxidant selected from propyl gallate, butylated hydroxyanisol, and butylated hydroxytoluene is disclosed. The pharmaceutical composition has an improved shelf life. In one embodiment, the composition additionally comprises sucrose, microcrystalline cellulose, and mannitol. The pharmaceutical composition may be used for treating thyroid disorders by orally administering the composition to a patient in need thereof.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.